NanoViricides, Inc. (NNVC) stock
NNVCNYSEPharmaceutical PreparationsFiscal year ends June 30
$1.23−0.12 (-8.89%)
Close on Nov 13, 2026Market cap $31.40MP/E –Yield –
NanoViricides r&d expenses
Research and development expenses are spending on new products and technology.
NanoViricides's R&D Expenses for the twelve months ending Jun 30, 2026 was $4.71M, down 15.2% year over year. For fiscal 2026 it was $4.71M, down 15.2% from the year before. Over ten years it grew -0.7% a year on average. The highest annual figure on record is $6.57M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $4.71M | -15.2% |
| FY2025 | Jun 30, 2025 | $5.55M | +2.1% |
| FY2024 | Jun 30, 2024 | $5.44M | -14.9% |
| FY2023 | Jun 30, 2023 | $6.39M | +10.5% |
| FY2022 | Jun 30, 2022 | $5.78M | -5.4% |
| FY2021 | Jun 30, 2021 | $6.11M | +30.2% |
| FY2020 | Jun 30, 2020 | $4.70M | -20.7% |
| FY2019 | Jun 30, 2019 | $5.92M | +0.1% |
| FY2018 | Jun 30, 2018 | $5.91M | -9.9% |
| FY2017 | Jun 30, 2017 | $6.57M | +30.6% |
| FY2016 | Jun 30, 2016 | $5.03M | +37.4% |
| FY2015 | Jun 30, 2015 | $3.66M | -28.7% |
| FY2014 | Jun 30, 2014 | $5.13M | +19.5% |
| FY2013 | Jun 30, 2013 | $4.29M | +0.6% |
| FY2012 | Jun 30, 2012 | $4.27M | +2.6% |
| FY2011 | Jun 30, 2011 | $4.16M | +23.4% |
| FY2010 | Jun 30, 2010 | $3.37M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $1.31M | +11.3% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $1.29M | +0.3% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $1.12M | -3.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $993.07K | -48.6% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $1.18M | -0.4% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $1.28M | +5.6% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $1.16M | -26.5% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $1.93M | +31.8% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $1.18M | -59.4% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $1.21M | +1.6% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $1.57M | +34.4% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $1.47M | +31.8% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $2.91M | +148.6% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $1.20M | -4.7% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $1.17M | -7.2% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $1.11M | -46.9% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $1.17M | -26.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $1.26M | -14.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $1.26M | -15.5% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $2.10M | +33.3% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $1.58M | +48.5% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $1.46M | +29.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $1.49M | +47.5% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $1.57M | +6.1% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $1.07M | -32.8% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $1.13M | -13.4% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $1.01M | -39.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $1.48M | +5.0% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $1.59M | +3.6% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $1.31M | +1.5% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $1.66M | +1.1% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.41M | -2.8% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $1.53M | -33.3% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $1.29M | -17.2% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $1.64M | +30.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $1.45M | -0.0% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $2.29M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $1.56M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $1.26M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $1.45M | – |
See a number that looks wrong?